# A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma

Source: https://onco.cc/trials/nct00434161/  
OnCo record `nct00434161` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Palifermin in Multiple myeloma, run by Swedish Orphan Biovitrum, completed.

## Summary

A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Multiple Myeloma is a phase 3 interventional study registered as NCT00434161 by Swedish Orphan Biovitrum, with 281 participants recorded, started 2006-12 and reaching its primary completion in 2009-03. Interventions recorded: Palifermin before only, Placebo, Palifermin before and after. Conditions recorded: Multiple Myeloma.

Linked to the drug Palifermin because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00434161
- Phase: 3
- Setting: A Double-Blind, Randomized, Placebo-controlled Study of Two Different Schedules of Palifermin for Reduction in Severity of Oral Mucositis in Subjects With Multiple Myeloma Receiving Melphalan Followed by Autologous Blood Stem Cell Transplantation
- Sponsor: Swedish Orphan Biovitrum
- Enrolled: 281

## Sources

- ClinicalTrials.gov NCT00434161: https://clinicaltrials.gov/study/NCT00434161

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Palifermin](https://onco.cc/drugs/palifermin/)
- companies: [Sobi (Swedish Orphan Biovitrum)](https://onco.cc/companies/sobi/)

---
JSON: https://onco.cc/api/v1/entities/nct00434161.json